Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, summarizes his article on the EV-301 study of enfortumab vedotin and its role in making the drug a standard treatment option for patients with urothelial cancer. Dr. Petrylak looks back at the phase 1 and 2 trials of enfortumab vedotin before going over how the 40% response rate observed in the phase 3 trial led to the accelerated approval of the drug for patients previously treated with either a platinum-based chemotherapy or checkpoint inhibitor. He concludes by sharing possible side effects and noting that there are several studies working towards making the drug part of first-line treatment.
15 окт 2024
